Literature DB >> 2473355

Atrial natriuretic factor administered to humans: 1984-1988.

A M Richards1.   

Abstract

In initial studies of human atrial natriuretic factor (ANF) administered to man, 100 microns intravenous bolus doses infused in normal volunteers and patients with essential hypertension resulted in clear increases in urinary excretion of sodium (four- to sixfold), urine volume, calcium, magnesium, and phosphorous. In addition, in both groups an acute but short-lived fall in blood pressure and rise in heart rate was observed. In these studies and other high dose constant infusion experiments, the response of the renin-angiotension-aldosterone system and plasma catecholamines was varied, either remaining unchanged or showing stimulation when high doses of ANF caused acute and substantial falls in blood pressure. In contrast, constant low-dose infusions of ANF in both normal and hypertensive man (0.75-2 pmol/kg/min) have consistently shown clear suppression of plasma concentrations of renin, angiotensin II, and aldosterone by at least 50% of baseline values. Such "physiological" doses of ANF are not associated with sympathetic nervous system activation even though subtle but significant falls in blood pressure (particularly systolic) may occur.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473355

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Intracerebroventricular administration of atrial natriuretic peptide prevents increase of plasma ADH, aldosterone and corticosterone levels in restrained conscious dehydrated rabbits.

Authors:  C Kallaras; N Angelopoulos; S Bountzioukas; K Mavroudis; M Karamouzis; O Guiba-Tziampiri
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

2.  Salt-sensitivity is associated with a hyperinsulinaemic and hyperglycaemic response to atrial natriuretic peptide infusion in human essential hypertension.

Authors:  C Ferri; C Bellini; G Desideri; L Di Francesco; G De Mattia; A Santucci; F Balsano
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

3.  Human pharmacokinetics of an analogue of atrial natriuretic factor.

Authors:  S H Ingwersen; H Eiskjaer; M Schmiegelow; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.